Effect of Therapy on Diabetic Macular Oedema

  • Samia Fatum
  • Elizabeth Pearce
  • Victor Chong


Anti-vascular endothelial growth factor (VEGF) therapies have changed the dynamics in the management of patients with diabetic macular oedema (DME); increasingly it is the treatment of choice when there is extensive oedema in foveal-involving DME. The role of laser in the anti-VEGF era has to be re-examined. Despite the efficacy of laser, the mechanism of laser treatment remains unclear. Armed with extensive clinical trial data and the experience of using anti-VEGF agents for DME, retinal specialists have found that a significant number of patients do not respond to anti-VEGF agents or require continuous monthly dosing. In these patients, steroids may be useful as an alternative or as adjunct therapy. Less than 10 years ago, we only had to decide whether to laser or not. At the time of writing in late 2015, we have three anti-VEGF agents in common use, two approved steroids, and several different new laser modalities as well as our old friend conventional laser. We should also not forget that vitrectomy may be useful in some cases, and pharmaceutical agent to release vitreomacular adhesion may be worth consideration in a few cases.


Retinal Pigment Epithelium Cell Diabetic Macular Oedema Posterior Vitreous Detachment Early Treatment Diabetic Retinopathy Study Central Subfield Thickness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, Park JY, Chung JY, Park KH, Woo SJ (2014) Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 55:567–573CrossRefPubMedGoogle Scholar
  2. Bandello F, Polito A, DelBorrello M, Zemella N, Isola M (2005) “Light” versus “classic” laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 89:864–870CrossRefPubMedPubMedCentralGoogle Scholar
  3. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM, Ozurdex CHAMPLAIN Study Group (2011) Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31:915–923CrossRefPubMedGoogle Scholar
  4. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914CrossRefPubMedGoogle Scholar
  5. Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M et al (2012) Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 130:1153–1161CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, Diabetic Retinopathy Clinical Research Network (2015) Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina 35:2516–2528CrossRefPubMedGoogle Scholar
  7. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, KapikB BK, Kane FE, Green K, FAME Study Group (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119:2125–2132CrossRefPubMedGoogle Scholar
  8. de Smet MD, Castilla M (2013) Ocriplasmin for diabetic retinopathy. Expert Opin Biol Ther 13:1741–1747CrossRefPubMedGoogle Scholar
  9. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, Cunha-Vaz JG, Chong NV (2009) Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 93:1341–1344CrossRefPubMedGoogle Scholar
  10. Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Writing Committee for the Diabetic Retinopathy Clinical Research Network et al (2007) Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 125:469–480CrossRefPubMedGoogle Scholar
  11. Korobelinik JF, Do DV, Schmidt-Erfurth U, Boyser DS, Holz FG, Heier JS et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 232:2247–2254CrossRefGoogle Scholar
  12. Lavinsky D, Cardillo JA, Melo LA Jr, Dare A, Farah ME, Belfort R Jr (2011) Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 52:4314–4323CrossRefPubMedGoogle Scholar
  13. Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34:87–97CrossRefPubMedGoogle Scholar
  14. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625CrossRefPubMedGoogle Scholar
  15. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801CrossRefPubMedGoogle Scholar
  16. Olk RJ (1990) Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 97:1101–1112CrossRefPubMedGoogle Scholar
  17. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B (2011) General pathophysiology of macular edema. Eur J Ophthalmol 6:S10–S19CrossRefGoogle Scholar
  18. Simunovic MP, Hunyor AP, Ho IV (2014) Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol 49:188–195CrossRefPubMedGoogle Scholar
  19. Stewart MW (2012) Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep 12:364–375CrossRefPubMedGoogle Scholar
  20. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E (2010) Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 30:908–916CrossRefPubMedGoogle Scholar
  21. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN et al (2015) Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Eng J Med 372:1192–1203Google Scholar

Copyright information

© Springer India 2017

Authors and Affiliations

  1. 1.Oxford Eye Hospital, Oxford University HospitalsOxfordUK
  2. 2.Department of OptometryMoorfields Eye HospitalLondonUK

Personalised recommendations